Latin America Benign Prostatic Hyperplasia Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacological treatmentAlpha-blockersTamsulosinSilodosinAlfuzosinDoxazosinOther alpha-blockers5-alpha reductase inhibitors (5-ARI)DutasterideFinasterideCombination therapyAlpha-blockers + 5-arisAlpha-blockers + pde5 inhibitorsPhosphodiesterase-5 inhibitors (pde5 inhibitors)Herbal and other drugs, Surgical treatmentTransurethral resection of the prostate (TURP)Transurethral incision of the prostate (TUIP)Open prostatectomyLaser therapyHolmium laser enucleation of the prostate (HOLEP)Photoselective vaporisation of the prostate (PVP), Minimally invasive proceduresUrolift systemRezūm water vapour therapyProstatic artery embolisationMicrowave thermotherapyTransurethral needle ablation (TUNA), Other treatmentsLifestyle modificationsWatchful waiting / active surveillance), By End Use (Hospitals, Clinics, Ambulatory surgical centres, Specialty urology centers), By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria) and Forecast, 2026-2034

Table of Contents

1. Executive Summary
   1. Introduction
2. Market Introduction
   1. Market Definition
   2. Scope of the Study
   3. Market Structure
3. Research Methodology
   1. Primary Research
   2. Research Methodology
   3. Assumptions & Exclusions
   4. Secondary Data Sources
4. Market Factor Analysis
   1. Value Chain Analysis: Latin America Benign Prostatic Hyperplasia Treatment Market
   2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
5. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
6. Recent Trends Analysis
7. Impact of COVID-19 on Latin America Benign Prostatic Hyperplasia Treatment Market
   1. Pre and Post Covid -19 Market Scenario Analysis
   2. Market Recovery Timeline and Challenge
   3. Measures Taken by Top Players
8. Regulatory Landscape
9. Latin America Benign Prostatic Hyperplasia Treatment Market, By Treatment Type
   1. Introduction
      1. Market Size and Forecast, By Treatment Type
   2. Pharmacological treatment
      1. Market Size and Forecast, By Region
      2. Alpha-blockers
         1. Market Size and Forecast, By Region
         2. Tamsulosin
            1. Market Size and Forecast, By Region
         3. Silodosin
            1. Market Size and Forecast, By Region
         4. Alfuzosin
            1. Market Size and Forecast, By Region
         5. Doxazosin
            1. Market Size and Forecast, By Region
         6. Other alpha-blockers
            1. Market Size and Forecast, By Region
      3. 5-alpha reductase inhibitors (5-ARI)
         1. Market Size and Forecast, By Region
         2. Dutasteride
            1. Market Size and Forecast, By Region
         3. Finasteride
            1. Market Size and Forecast, By Region
      4. Combination therapy
         1. Market Size and Forecast, By Region
         2. Alpha-blockers + 5-aris
            1. Market Size and Forecast, By Region
         3. Alpha-blockers + pde5 inhibitors
            1. Market Size and Forecast, By Region
      5. Phosphodiesterase-5 inhibitors (pde5 inhibitors)
         1. Market Size and Forecast, By Region
      6. Herbal and other drugs
         1. Market Size and Forecast, By Region
   3. Surgical treatment
      1. Market Size and Forecast, By Region
      2. Transurethral resection of the prostate (TURP)
         1. Market Size and Forecast, By Region
      3. Transurethral incision of the prostate (TUIP)
         1. Market Size and Forecast, By Region
      4. Open prostatectomy
         1. Market Size and Forecast, By Region
      5. Laser therapy
         1. Market Size and Forecast, By Region
         2. Holmium laser enucleation of the prostate (HOLEP)
            1. Market Size and Forecast, By Region
         3. Photoselective vaporisation of the prostate (PVP)
            1. Market Size and Forecast, By Region
   4. Minimally invasive procedures
      1. Market Size and Forecast, By Region
      2. Urolift system
         1. Market Size and Forecast, By Region
      3. Rezūm water vapour therapy
         1. Market Size and Forecast, By Region
      4. Prostatic artery embolisation
         1. Market Size and Forecast, By Region
      5. Microwave thermotherapy
         1. Market Size and Forecast, By Region
      6. Transurethral needle ablation (TUNA)
         1. Market Size and Forecast, By Region
   5. Other treatments
      1. Market Size and Forecast, By Region
      2. Lifestyle modifications
         1. Market Size and Forecast, By Region
      3. Watchful waiting / active surveillance
         1. Market Size and Forecast, By Region
10. Latin America Benign Prostatic Hyperplasia Treatment Market, By End Use
    1. Introduction
       1. Market Size and Forecast, By End Use
    2. Hospitals
       1. Market Size and Forecast, By Region
    3. Clinics
       1. Market Size and Forecast, By Region
    4. Ambulatory surgical centres
       1. Market Size and Forecast, By Region
    5. Specialty urology centers
       1. Market Size and Forecast, By Region
11. Latin America Benign Prostatic Hyperplasia Treatment Market, By Patient Age Group
    1. Introduction
       1. Market Size and Forecast, By Patient Age Group
    2. Below 50 years
       1. Market Size and Forecast, By Region
    3. 50–60 years
       1. Market Size and Forecast, By Region
    4. Above 60 years
       1. Market Size and Forecast, By Region
12. Latin America Benign Prostatic Hyperplasia Treatment Market, By Distribution Channel
    1. Introduction
       1. Market Size and Forecast, By Distribution Channel
    2. Hospital pharmacy
       1. Market Size and Forecast, By Region
    3. Retail pharmacy
       1. Market Size and Forecast, By Region
    4. Online pharmacy
       1. Market Size and Forecast, By Region
13. Regional Overview
    1. Introduction
       1. Market Size and Forecast
    2. Latin America
       1. Market Size and Forecast
          1. By Treatment Type
             1. Pharmacological treatment
             1. Alpha-blockers
             1. Tamsulosin
             2. Silodosin
             3. Alfuzosin
             4. Doxazosin
             5. Other alpha-blockers
             2. 5-alpha reductase inhibitors (5-ARI)
             1. Dutasteride
             2. Finasteride
             3. Combination therapy
             1. Alpha-blockers + 5-aris
             2. Alpha-blockers + pde5 inhibitors
             4. Phosphodiesterase-5 inhibitors (pde5 inhibitors)
             5. Herbal and other drugs
             2. Surgical treatment
             1. Transurethral resection of the prostate (TURP)
             2. Transurethral incision of the prostate (TUIP)
             3. Open prostatectomy
             4. Laser therapy
             1. Holmium laser enucleation of the prostate (HOLEP)
             2. Photoselective vaporisation of the prostate (PVP)
             3. Minimally invasive procedures
             1. Urolift system
             2. Rezūm water vapour therapy
             3. Prostatic artery embolisation
             4. Microwave thermotherapy
             5. Transurethral needle ablation (TUNA)
             4. Other treatments
             1. Lifestyle modifications
             2. Watchful waiting / active surveillance
          2. By End Use
             1. Hospitals
             2. Clinics
             3. Ambulatory surgical centres
             4. Specialty urology centers
          3. By Patient Age Group
             1. Below 50 years
             2. 50–60 years
             3. Above 60 years
          4. By Distribution Channel
             1. Hospital pharmacy
             2. Retail pharmacy
             3. Online pharmacy
       2. Brazil
          1. By Treatment Type
             1. Pharmacological treatment
             1. Alpha-blockers
             1. Tamsulosin
             2. Silodosin
             3. Alfuzosin
             4. Doxazosin
             5. Other alpha-blockers
             2. 5-alpha reductase inhibitors (5-ARI)
             1. Dutasteride
             2. Finasteride
             3. Combination therapy
             1. Alpha-blockers + 5-aris
             2. Alpha-blockers + pde5 inhibitors
             4. Phosphodiesterase-5 inhibitors (pde5 inhibitors)
             5. Herbal and other drugs
             2. Surgical treatment
             1. Transurethral resection of the prostate (TURP)
             2. Transurethral incision of the prostate (TUIP)
             3. Open prostatectomy
             4. Laser therapy
             1. Holmium laser enucleation of the prostate (HOLEP)
             2. Photoselective vaporisation of the prostate (PVP)
             3. Minimally invasive procedures
             1. Urolift system
             2. Rezūm water vapour therapy
             3. Prostatic artery embolisation
             4. Microwave thermotherapy
             5. Transurethral needle ablation (TUNA)
             4. Other treatments
             1. Lifestyle modifications
             2. Watchful waiting / active surveillance
          2. By End Use
             1. Hospitals
             2. Clinics
             3. Ambulatory surgical centres
             4. Specialty urology centers
          3. By Patient Age Group
             1. Below 50 years
             2. 50–60 years
             3. Above 60 years
          4. By Distribution Channel
             1. Hospital pharmacy
             2. Retail pharmacy
             3. Online pharmacy
       3. Mexico
       4. Argentina
       5. Chile
       6. Colombia
       7. Rest of Latin America
14. Competitive Landscape, 2025
    1. Introduction
    2. Latin America Benign Prostatic Hyperplasia Treatment Market Share Analysis, 2025 (%)
       1. Market Share Analysis, 2025
       2. Competition Ranking, 2025
       3. Key Developments & Growth Strategies
          1. Merger & Acquisition
          2. Product Launch
          3. Expansion
       4. Consolidated SWOT Analysis of Key Players
15. Company Profile
    1. Boston Scientific Corporation
       1. Business Overview
       2. Financial Data
       3. Key Product domains
       4. Recent Developments
    2. Teleflex Incorporated
    3. Olympus Corporation
    4. KARL STORZ SE & Co. KG
    5. Richard Wolf GmbH
    6. Cook Medical
    7. Medtronic plc
    8. Johnson & Johnson
    9. Astellas Pharma Inc.
    10. GSK plc
    11. Sanofi
    12. Viatris Inc.
    13. Boehringer Ingelheim
    14. Bayer AG
    15. Terumo Corporation